TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

TScan Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.21−0.02 (-9.00%)

Close on Oct 19, 2026

Market cap: $27.32M
P/E (TTM): –
Dividend yield: –

TScan Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	10	2.82	21	14	10	1.09
Research & Development	114	107	88	60	45	21
General & Administrative	32	30	26	20	14	6.74
Operating Expenses	146	138	115	80	59	27
Operating Income	-136	-135	-93	-67	-49	-26
Interest Expense	2.77	3.65	3.76	1.18	–	–
Other Non-Operating Income	6.05	7.32	4.24	0.42	0.02	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	0.00
Income Tax Expense	0	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-130	-127	-89	-66	-49	-26
Net Income	-130	-127	-89	-66	-49	-26
EPS (Basic)(per share)	-1.00	-1.14	-1.36	-2.75	-4.17	-28.52
EPS (Diluted)(per share)	-1.00	-1.14	-1.36	-2.75	-4.17	-28.52
Shares Outstanding (Basic, Weighted)(shares)	130	112	66	24	12	0.92
Shares Outstanding (Diluted, Weighted)(shares)	130	112	66	24	12	0.92
EBITDA	-133	-131	-88	-62	-45	-25

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1695.1%
Net margin: -1655.4%
Return on equity, FY2025: -71.3%

Financial strength

Current ratio: 3.37
Debt to equity: 0.47
Debt to assets: 19.1%
Cash to current liabilities: 323.5%

Valuation

P/E ratio: –
Price to sales: 3.84
Price to book: 0.40
Dividend yield: –